This week’s announcements include the retirement of GlaxoSmithKline’s CFO, new CEOs at Complexa, Synlogic and Horizon Discovery, and other new hires at TP Therapeutics and Motif Bio, and a new board member at DBV Technologies.

Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.

The US firm brings in advisors as it considers its options after the Phase III ADAPT study of its cancer immunotherapy fails even after change to protocol.

2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.

This week's appointments include new R&D heads at Novartis and GSK, while LNC Therapeutics gets a new CEO, Plus announcements from Zelluna and BC Platforms.

The number of products in active development by the pharma and biotech industries has topped 15,000 for the first time but the rate of the pipeline growth has slowed to just 2.7%, the lowest for five years, shows a new analysis by Citeline.